超血是患有高血压的患者血管反应性损伤的风险因素
I-Min Su1,2,3, Li-Liang Chuang4,5, Ji-Hung Wang2,4,6
1Department of Anesthesiology, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chiayi 62247, Taiwan.
Medicina (Kaunas, Lithuania)
|December 31, 2025
概括
较高的瘦素水平与高血压患者的血管反应性较差有关. 这一发现表明丁可能是高血压中心血管疾病风险的早期生物标志物.
科学领域:
- 心血管医学 心血管医学
- 内分泌学 在内分泌学.
- 血管生物学 血管生物学
背景情况:
- 内皮功能障碍是高血压中心血管疾病的早期迹象.
- 一种阿迪波金 (adipokine) 类型的瘦素会影响血管平衡,但其在高血压血管活性中的作用尚不清楚.
研究的目的:
- 在高血压患者中研究血清瘦素水平和血管反应性之间的关联.
主要方法:
- 一项对100名高血压患者的横截面研究.
- 使用数字热监测来计算血管反应指数 (VRI) 的评估血管反应.
- 统计分析包括相关性,逻辑回归,线性回归和ROC分析.
主要成果:
- 较高的血清瘦素水平与VRI受损显著相关 (p < 0.001).
- 丁是血管反应功能障碍 (OR=1.096) 和反应性差 (OR=1.197) 的独立预测因子.
- 莱普与VRI负相关 (r=-0.408) 和独立确定的VRI (β=-0.296).
结论:
- 血清勒丁水平升高与高血压中血管反应能力受损独立相关.
- 丁可以作为一种潜在的生物标志物,用于在高血压患者中早期检测血管功能障碍.
相关概念视频
Overview of Lipid Metabolism
4.7K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.7K
Hypertension III: Clinical Manifestations and Diagnostic Studies
437
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
437
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516
Hypertension and Regulation of Blood Pressure
3.6K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.6K
Hypertension II: Pathophysiology
700
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
700
Hypoglycemia and Glucagon
766
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
766


